Wednesday, April 3, 2013
Sunday, March 10, 2013
Wednesday, February 3, 2010
MPEP Random
Sunday, January 10, 2010
Patent Bar Study for Free
Monday, October 8, 2007
I am creating artificial life, declares US gene pioneer
Craig Venter, the controversial DNA researcher involved in the race to decipher the human genetic code, has built a synthetic chromosome out of laboratory chemicals and is poised to announce the creation of the first new artificial life form on Earth. ( The Guardian)
Nobel Season and a note on RNA
Interesting to note:
The Nobel in Medicine has gone this year to the inventors of gene-knockout techniques for mice, which seems well-deserved, considering how much has been learned through such experiments. This is, in fact, one of those discoveries that you'd think was already recognized by a Nobel if you hadn't been keeping count, which is as good a criterion as any. (It's rather odd, for example, that gene knockouts were recognized after RNA interference, don't you think, since a good ten or fifteen years separate the two in real life?)
My previous post noted that over 46,000 hits came up for "knock-out mice" search on PubMed. Interesting, RNAi gets only 9868, Certainly not a perfect measures but informative on some level.
Nobel Season. In the Pipeline:
"... Wednesday morning is the announcement of the Chemistry award, so I'm throwing open the gates of speculation, as I do every year around here. Our track record (mine and the predictions in the comments) has not been very good, but nobody has a good batting average when trying to read the minds of the Nobel committees. I feel pretty safe in saying that this year will be a "real" chemistry prize - we're one out of the last four, compared to overflow from the nonexistent Nobel in molecular and cell biology.
So, who's it going to be? Last year's uninformed gossip is here, and there's plenty more over at Chembark. Put your bets down, but only with money you can afford to lose. . .
Update: Still more speculation."
Three Americans Win Noble Prize for Medicine
work in gene targeting, a process using homologous recombination to
turn off a single gene. When used in mice it is known as using
"knock-out mice", as that gene has been knocked out. Having a single
gene, and only that gene, turned off helps to understand how that gene
functions.
The two Americans are Mario R. Capecchi and Oliver Smithies. Sir
Martin J. Evans is British.
To give an idea of how important this technique is today, a search on
pub med, the medical research literature database, for "knock-out
mice" gives you over 46,820 research papers.
Monday, September 10, 2007
New Cure for Depression: Fear (DrugWonks)
Public Perception Of Biotechnology
Find these answers in the latest issue of Biotechnology Journal, devoted to 'Talking Biotech with the Public' which will be entirely FREE for download during the month of September 2007, at http://www.biotechnology-journal.com/. "
SignOnSanDiego.com > News > Business -- Technology giants, banking firms win major victory with House approval of patent reform bill
Opponents of the bill included pharmaceutical and biotechnology companies, such as Johnson & Johnson and Amgen Inc., who say it weakens patent protection by reducing infringement penalties and permitting post-approval challenges to patents. ...
The Senate Judiciary Committee approved a similar version of the bill in July and it awaits a vote in the full Senate.
That bill includes a provision that would protect banks from damage awards in patent infringement cases involving electronic check-clearing technologies, such as check-imaging systems.
Banks have paid millions of dollars to settle allegations of infringement of such technologies, the American Bankers Association said in July.
"Patent Docs: Patent "Reform" Bill Passes House of Representatives
Off Label Juice
I've also noticed a lot of college kids buying it to cure hangovers. Who knew.
"As beverage giants add vitamins, electrolytes, bright colors and flavors to their bottles in search of the next best-seller, Abbott Laboratories has won some converts — without even trying. Scores of amateur and professional athletes are hooked on Pedialyte, a liquid meant to quickly rehydrate toddlers experiencing diarrhea, the New York Times reports . The fluid, which comes in bubble gum and other kid-friendly flavors, contains the basic ingredients in most sports drinks. Abbott doesn’t market its product as a sports drink, nor does it track its sales to athletes, but company doctors say they’re aware of off-label locker-room use and that Pedialyte does work on the field. “It’d be different if they were drinking formula,” the Minnesota Vikings’ coach told The St. Paul Pioneer Press last year. “But Pedialyte is used in hospitals throughout the United States for hydration. It’s different than just your regular sports drink.”"
Friday, September 7, 2007
Health Business Blog � Blog Archive � No biogeneric legislation this year
Biogeneric legislation is not happening just yet. And Health Business Blog adds:
"I’m hopeful that the biogeneric push –which apes the path taken for generic versions of traditional drugs– will be rerouted. The newer proposals are not terrible, but my preference is for price regulation of biotech drugs post-patent expiry. No biogenerics or “biosimilars,” no new clinical trials, FDA inspections and reviews. Rather, same drugs, same factories, same processes, lower prices."
Wednesday, September 5, 2007
RGJ.com: Popcorn maker changes butter chemical
The smell of movie popcorn. Seems so unfair.
Tuesday, September 4, 2007
All Mapped Out - Forbes.com
So where does this leave Ventor's patent on a gene chassis?
Health Business Blog � Blog Archive � Are we really 99.9 percent identical? No.
Putting some perspective on recent genetics news.
Sector Glance: Biotech Stocks Rise - Forbes.com
"Porges also said the regulatory environment, despite some high profile safety driven labeling changes, is relatively benign for biotech companies.I'm not sure I agree with that, but we'll see.
'Biotech companies tend to be developing and marketing treatments for serious, often life-threatening illness. Such treatments are not subject to the same risks of rare serious side effects in broad usage,' he wrote."